Prosecution Insights
Last updated: November 04, 2026
Application No. 18/064,219

ENHANCED IMMUNOGENIC DNA/RNA COMPOSITIONS AND METHODS

Final Rejection §103§112
Filed
Dec 09, 2022
Priority
Jun 11, 2020 — provisional 63/038,117 +3 more
Examiner
QIAN, CELINE X
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mbf Therapeutics Inc.
OA Round
2 (Final)
48%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
377 granted / 794 resolved
-12.5% vs TC avg
Strong +17% interview lift
Without
With
+17.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
58 currently pending
Career history
847
Total Applications
across all art units

Statute-Specific Performance

§101
8.0%
-32.0% vs TC avg
§103
29.6%
-10.4% vs TC avg
§102
18.0%
-22.0% vs TC avg
§112
36.3%
-3.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 794 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 2, 5-9, 11, 13-16, 21-30 are pending in the application. Claims 21 and 22 are withdrawn. Claims 1, 2, 5-9, 13-16, 23-30 are currently under examination. This office action is in response to the amendment filed on 6/8/2026. All previous rejection not reiterated in this office action are withdrawn. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 2, 5-9, 13-16, 23-30 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Amended claim 1 is amended to introduce a new limitation “polycation functionalized calcium phosphate nanoparticles that have a maximum size in any dimension of 150 micron or less.” Applicant states that this limitation is supported in present specification in paragraphs [0799], [0804] and [0809]. Upon reviewing the specification, the only paragraph that describes the size of calcium phosphate nanoparticles is paragraph [0804], which starts with CEPESC comprise DA less than 2 microns in size…then continues with less than 1 micron, less than 0.7 micron…and goes on to nanometer ranges. Nowhere in the specification describes “nanoparticles” that has maximum size 150 microns. Therefore, this amendment that is added after the filing of the application, comprises new matter. Dependent claims 2, 5-9, 13-16, 23-30 that depends on claim 1, also comprises new matter. Newly added claims 27 and 29 recites the limitation that “wherein the triclosan selection sequence is expressed in bacterial cells and not in mammalian cells.” Applicant points to paragraphs [0209]-[0210], [0861] and [0877] in specification to support this limitation. Upon reviewing the specification, these cited paragraph does not fully support the limitation “not in mammalian cells.” Paragraph [0209]-[0210] describes different types of selection markers, and lists triclosan as one of the selection agents based on host cells tolerance to this biocide induced by overexpression of fabI gene. Paragraph [0861] describes generally plasmid vectors may comprise expression enhancing intron, a strong promoter, a reporter gene and a non-antibiotic resistance system such as triclosan selection system, and there is no description of any host cells in which the gene is expressed. Paragraph [0877] describes all early and immediate early genes from 39 strains of ASFV critical for replication will be identified and cloned into plasmid. The only relevant sentence to triclosan is “the plasmid also carries the FabI gene for triclosan non-antibiotic selection and plasmid amplification.” In the context of the cited paragraphs, the only support may be inferred it that selection sequence is expressed in bacterial cells (for plasmid amplification). However, there is no support for the negative limitation “not in mammalian cells.” Since this newly added limitation is introduced after the filing of the present application, this limitation constitutes new matter. Newly added claim 30 recites the limitation of “the at least two DNA molecules further comprises one or more nucleotide sequences encoding at least one innate trained immunity cell immunomodulator.” Applicant cites specification paragraphs [0388], [0441] and [0828] to support this limitation. Paragraph [0388] describes innate trained immunity immunomodulators (ITIPIMs), and give examples of PCMs that exhibit significant IRs in DCs include modulators of DEC-205, Langerin…etc. Paragraph [0441] gives more examples of ITIIM. Paragraph [0828] describes “innate trained immunity” but does not teach compositions that comprises the claimed composition with additional nucleic acid sequence encoding at least one innate trained immunity cell immunomodulator. Since this newly added limitation is introduced after the filing of the present application, this limitation constitutes new matter. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 2, 5-9, 13-16, 23-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. This is a new ground of rejection necessitated by amendment. Regarding claim 1, the recitation of “nanoparticles that have a maximum size in any dimension of 150 microns or less” renders the claim indefinite because the claimed size range 150 microns or less encompasses sizes that are not considered to be nanoparticles. The claim thus claims a broader range and a narrower range of the calcium phosphate particles such that the metes and bounds of the claim cannot be established. Dependent claims 2, 5-9, 13-16, 23-30 are rejected for same reason because they depend on claim 1 but does not remedy such indefiniteness. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 5-7, 13, 14 and 16 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ledebur (WO 99/24596) in view of Bell (US 2002/0068090) and Sokolova (J. Mater Sci, 2010, Vol.45, pages 4952-4957). This is a new ground of rejection necessitated by amendment. Amended claim 1 is drawn to a composition comprising the following components: 1) an effective amount of at least two DNA molecules encoding different products: a) a first DNA molecule comprising one or more antigens that induce an immune response against a disease causing agent; and b) a second DNA molecule comprising i) one or more additional nucleotide sequences that induce an immune response against the disease causing agent and ii) one or more polyubiquitin sequences; 2) one or more types of polycation functionalized calcium phosphate (CaP) nanoparticles that have a maximum size of 150 microns or less that are associated with at least some of the at least two DNA molecules; (3) one or more additional adjuvant compositions. Ledebur teaches improved plasmids and methods for nucleic acid vaccines that uses epitopes that are capable of inducing both cellular and humoral responses that result in a protective or therapeutic immune response against pathogens (abstract). Ledebur teaches if multiple epitopes are expressed in the context of a synthetic gene construct, immunity against many antigenic targets, multiple strain variants or multiple pathogens is possible (page 4, last paragraph). Ledebur teaches multivalent expression systems that comprises two plasmids, two genes, IRES or alternative splicing that express such epitopes (Figure 8, page 5, lines 22-26). Ledebur teaches for effective nucleic acid based vaccines, it may be important to have the capability of expressing multiple antigens or multiepitope gene product, which may enhance the potency of these vaccines (page 18, lines 1-7). Ledebur teaches it is advantageous to encode polyubiquitin chain to antigenic epitopes because expression plasmids with Ub fused to the antigen have been used to achieve class I presentation (page 9, lines 11-20). However, Ledebur does not teach the inclusion of polycation-functionalized calcium phosphate nanoparticles that have a maximum 150 microns or less are associated with some of the two DNA, and the inclusion of additional adjuvant compositions. Bell teaches a formulation of CaP for use as a mucosal adjuvant (paragraph [0040], lines 1-2). Bell teaches the core CaP particles having a diameter between 300nm to 4000nm that can deliver a native or recombinant immunogen to mucosal surface (paragraph [0041]). Bell teaches that the CaP formulation may be compounded with any physiologically acceptable vehicle or other complementary immunological adjuvant and applied directly to the mucosal surface tissue (paragraph [0048]). Sokolova teaches an outer shell of positively charged poly(ethyleneimine) (PEI) strongly increases the transfection efficiency of calcium phosphate/DNA nanoparticles (title). Sokolova teaches polycationic polymers like PEI form aggregates with DNA, which can be used for non-viral gene delivery, wherein the positive charge of the resulting aggregates is beneficial for penetrating the cell membrane (page 4953, 1st col.,2nd paragraph). Sokolova teaches that CaP/DNA functionalized with PEI has a size around 285 or 150 nm (Table 1). Sokolova teaches that PEI functionalized CaP/DNA has increased transfection efficiency and cell viability compared to standard calcium phosphate (Table 3 and legend). It would have been obvious to an ordinary skilled in the art reading Ledebur to add one or more types of polycation functionalized calcium phosphate nanoparticles to the nucleic acid based vaccine composition based on the combined teaching from Bell and Sokolova. The ordinary skilled in the art would be motivated to add calcium phosphate nanoparticle taught by Bell to the vaccine composition because Bell demonstrates CaP nanoparticle is an effective adjuvant in mucosal vaccine delivery. The ordinary skilled in the art would be motivated to functionalize the CaP nanoparticles with polycation (PEI) as taught by Sokolova to further increase the ability for said CaP nanoparticle to cross the cell membrane efficiently. Bell also teaches that when using CaP nanoparticle as adjuvant, additional adjuvant may be included in the composition. Therefore, the claimed invention of claim 1 would have been prima facie obvious to an ordinary skilled in the art at the time the application was filed. Regarding claim 5, Ledebur teaches the use of epitopes, small immunologically relevant protein sequences that are capable of inducing both cellular and humoral responses would result in a protective or therapeutic immune response against pathogens (abstract). Bell also teaches a desirable immune response to an immunogenic polypeptide is two-fold, involving both humoral and cell mediated immunity, wherein the humoral component is manifested following stimulating B cells, and cellular mediated immunity involves T lymphocytes capable of recognizing intracellular pathogens (paragraph [0028]). It would have been obvious to an ordinary skilled in the art to include antigen or epitopes thereof that induces both B cell and T cell mediated response in the vaccine composition because it offers better protection to the disease causing agent. Whether said epitopes are included in one DNA molecule, two DNA molecules would have been routine optimization rather than method of innovation. Therefore, the claimed invention of claim 5 would have been prima facie obvious to an ordinary skilled in the art at the time the application was filed. Regarding claims 6, 7, 13, 14, Bell teaches CaP nanoparticles further includes carbohydrate derivatives (paragraph [0087]). Regarding claim 16, Ledebur teaches multiple antigens or epitope gene product expressed by vaccine (page 18, 1st paragraph), at least epitope gene product meets the limitation “an amino acid sequence that is identical to the amino acid sequence of one or more naturally occurring epitope contained in an antigenic polypeptide that is expressed by the disease causing agent” because it is well known in the art that epitopes are isolated from polypeptide expressed by disease causing agent such as viruses or bacteria. Claim(s) 2, 9, 23-25, 27-30 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ledebur, Bell and Sokolova, as applied to claims 1, 5-7, 13, 14 and 16 above, and further in view of Goh et al (BMC Biotechnology, 2008, Vol.8: 61, pages 1-9). This is a new ground of rejection necessitated by amendment. The teaching from Ledebur, Bell and Sokolova has been discussed above. However, none of the references teaches the selection sequence of triclosan system . Goh teaches antibiotic resistance genes are widely used for selection of recombinant bacteria, but their use risks contributing to spread of antibiotic resistance, particularly the practice is inappropriate for vaccine production (abstract). Goh teaches fabI marker plasmid selection by triclosan in E. coli, which out performed the parent antibiotic system (page 2, 1st col., 4th paragraph). Goh teaches fabI expression is induced by arabinose in E.coli, under Pbad promoter (page 4, 2nd col., last 2 paragraphs). It would have been obvious to an ordinary skilled in the art to further include a non-antibiotic selection marker in the plasmids taught by Ledebur for producing said plasmids in bacterial cell. The ordinary skilled in the art would be motivated to use triclosan selection system as taught by Goh because Goh teaches antibiotic selection is inappropriate for vaccine production, and demonstrates that fabI expression in E. coli produces efficient selection of plasmids. The ordinary skilled in the art would thus have reasonable expectation of success to include a triclosan selection sequence, fabI, in the plasmid taught by Ledebur following combined teaching from Ledebur and Goh. Therefore, the claimed invention of claims 2, 23, 27, and 29 would have been prima facie obvious to an ordinary skilled in the art at the time the application was filed. Regarding claims 9 and 28, Ledebur teaches multiple antigens or epitope gene product expressed by vaccine (page 18, 1st paragraph), at least epitope gene product meets the limitation “an amino acid sequence that is identical to the amino acid sequence of one or more naturally occurring epitope contained in an antigenic polypeptide that is expressed by the disease causing agent” because it is well known in the art that epitopes are isolated from polypeptide expressed by disease causing agent such as viruses or bacteria. Regarding claims 24 and 25, Bell teaches CaP nanoparticles further includes carbohydrate derivatives (paragraph [0087]). Regarding claim 30, Ledebur teaches for effective nucleic acid based vaccines, co-expression of costimulatory proteins, including IL-2 and GM-CSF have been demonstrated to enhance the immune response to an encoded antigen (page 18, line 7-10). It would have been obvious to an ordinary skilled in the art to include nucleotide sequence encoding GM-CSF to the expression cassette that expresses the antigen based on such teaching. Based on the knowledge in prior art as evidence by the teaching from Mulder (Nature reviews, 2019, Vol.18, pages 553-566), GM-CSF controls trained immunity (Figure 2 and legend, page 555, 1st col., 1st paragraph) and meets the limitation of innate trained immunity cell immunomodulator. Claim(s) 8 , 11, 15 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ledebur, Bell and Sokolova, as applied to claims 1, 5-7, 13, 14 and 16 above, and further in view of Jin (cited previously). This is a new ground of rejection necessitated by amendment. The teaching from Ledebur, Bell and Sokolova has been discussed above. However, none of the reference specially teaches βglucan as immunoadjuvant. Jin teaches βglucan is a group of polysaccharides exits in many organism species including mushroom, yeast, oats, barley, seaweed and have a variety of biological activities (abstract). Jin teaches βglucan can regulate immune responses when administered alone and can connect innate and adaptive immunity to improve immunogenicity of vaccines (Table 2, page 5238, 1st col., 2nd paragraph, 2nd col., 2nd paragraph, and Table 3). It would have been obvious to an ordinary skilled in the art that βglucan may be used as an adjuvant to the vaccine composition render obvious by Ledebur, Bell and Sokolova. The ordinary skilled in the art would be motivated to use βglucan adjuvant because of its known immuno-potentiating effect taught by Jin, and would have reasonable expectation of success following combined teaching from Ledebur, Bell, Sokolova and Jin. Therefore, the claimed invention of claims 8 and 15 would have been prima facie obvious to an ordinary skilled in the art at the time the application was filed. Regarding claim 11, Ledebur teaches multiple antigens or epitope gene product expressed by vaccine (page 18, 1st paragraph), at least epitope gene product meets the limitation “an amino acid sequence that is identical to the amino acid sequence of one or more naturally occurring epitope contained in an antigenic polypeptide that is expressed by the disease causing agent” because it is well known in the art that epitopes are isolated from polypeptide expressed by disease causing agent such as viruses or bacteria. Claim(s) 26 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ledebur, Bell, Sokolova and Goh, as applied to claims 2, 9, 23-25, 27, 28 and 29 above, and further in view of Jin. This is a new ground of rejection necessitated by amendment. The teaching from Ledebur, Bell Sokolova and Goh has been discussed above. However, none of the reference specially teaches βglucan as immunoadjuvant. Jin teaches βglucan is a group of polysaccharides exits in many organism species including mushroom, yeast, oats, barley, seaweed and have a variety of biological activities (abstract). Jin teaches βglucan can regulate immune responses when administered alone and can connect innate and adaptive immunity to improve immunogenicity of vaccines (Table 2, page 5238, 1st col., 2nd paragraph, 2nd col., 2nd paragraph, and Table 3). It would have been obvious to an ordinary skilled in the art that βglucan may be used as an adjuvant to the vaccine composition render obvious by Ledebur, Bell, Sokolova and Goh. The ordinary skilled in the art would be motivated to use βglucan adjuvant because of its known immuno-potentiating effect taught by Jin, and would have reasonable expectation of success following combined teaching from Ledebur, Bell, Sokolova and Jin. Therefore, the claimed invention of claims 26 would have been prima facie obvious to an ordinary skilled in the art at the time the application was filed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CELINE X QIAN whose telephone number is (571)272-0777. The examiner can normally be reached M-F (8-4:00). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at 571-272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CELINE X QIAN/ Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Dec 09, 2022
Application Filed
Feb 24, 2025
Response after Non-Final Action
Feb 06, 2026
Non-Final Rejection mailed — §103, §112
Jun 08, 2026
Response Filed
Aug 18, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773446
METHODS TO STIMULATE IMMUNE RESPONSES TO MUTANT RAS USING NUCLEATED CELLS
3y 9m to grant Granted Oct 27, 2026
Patent 12721886
Virus-like particles containing CST1 protein and toxoplasma vaccine using same
3y 9m to grant Granted Sep 01, 2026
Patent 12715906
SINGLE CHAIN VH AND HEAVY CHAIN ANTIBODIES
4y 2m to grant Granted Aug 25, 2026
Patent 12685775
OLIGONUCLEOTIDES WITH NUCLEOSIDE ANALOGS
4y 3m to grant Granted Jul 21, 2026
Patent 12649699
PHOSPHATE SENSING MICROBIAL GENE SWITCH
1y 4m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
48%
Grant Probability
65%
With Interview (+17.3%)
3y 8m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 794 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month